Fig. 1

Patient and their related matched pre-treatment and relapse samples characteristics. a Absolute lymphocyte counts and lymphadenopathy of the patients during venetoclax therapy. Day zero marks the start of the venetoclax treatment. Green lines show the time points of sample collection. Computer tomography (CT) scans for staging were performed at the time points marked by red lines. b Results from whole-exome sequencing are shown, including: number of somatic mutations, sample ploidy, percent of the genome undergoing copy number alterations (blue for losses and red for gains), and cancer-related gene mutations with pronounced clonal dynamics during therapy. Genomic alterations are annotated according to the color panel below the image. Sample type/compartment and the status if a patient has undergone a Richter’s transformation are additionally indicated. Pre-treatment samples (T0) are shown in red. c Giemsa, Ki67, CD3, and CD274 stains from lymph node material of patient C811 after relapse from venetoclax. High protein levels of CD274 are consistent with the genomic amplification of the locus containing CD274. Scale bar, 100 µm